Abstract
It is important for Allergists/Immunologists to understand the risks and benefits of monoclonal antibodies (mAbs), which include unknown future risks especially for recently approved mAbs. We sought to estimate the potential risk of a future postmarket black box warning (BBW) in FDA-approved mAbs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
